CorMedix Inc.
Close on Oct 19, 2026
- Market cap
- $682.50M
- P/E (TTM)
- 3.6
- Dividend yield
- –
About CorMedix
Pharmaceutical Preparations, SIC 2834
CorMedix Inc. is a biopharmaceutical company that develops and commercializes therapeutic products for life-threatening conditions. Its primary commercial product is DefenCath, an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients using central venous catheters. Through its Melinta Therapeutics subsidiary, the company also markets infectious disease and cardiovascular medications, including REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. CorMedix provides these treatments to healthcare providers across various clinical settings, including inpatient hospitals, outpatient dialysis centers, emergency departments, outpatient clinics, and home infusion care facilities.
The company conducts its commercial operations in the United States, where its contracted customer base spans approximately 60% of outpatient dialysis facilities through agreements with large and mid-sized dialysis organizations. CorMedix is headquartered in Parsippany, New Jersey.
Summary of the business section of CorMedix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CorMedix Inc.
- Headquarters
- Parsippany, NJ
- Address
- 389 Interpace Pkwy, Suite 450 07054
- Phone
- (908) 517-9500
- Employees
- 191, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C, Morristown, New Jersey
Stock & identifiers
- Ticker
- CRMD
- Exchange
- Nasdaq
- IPO date
- Mar 26, 2010
- Shares outstanding
- 78M, Aug 10, 2026
- Public float
- $909.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-5 reverse, Mar 26, 2019
- SEC CIK
- 1410098
- CUSIP
- 21900C308
- ISIN
- US21900C3088
- LEI
- 5299006YIA3L0MBW8358
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Joseph Todisco | Chief Executive Officer, Director | 774,749 |
| Kaufman Beth Zelnick | Chief Legal Officer | 260,684 |
| Elizabeth Hurlburt | Chief Operating Officer | 270,463 |
| Susan Blum | Chief Financial Officer | 124,315 |
| Michael David Seckler | Chief Commercial Officer | 133,156 |
| Matthew T. David | Chief Financial Officer | 95,270 |
| Erin Mistry | EVP, Chief Commercial Officer | 100,992 |
| Janet Dillione | Director | 117,835 |
| Robert A. Stewart | Director | 66,453 |
| Myron Kaplan | Director | 261,487 |
| Gregory Scott Duncan | Director | 68,786 |
| Steven W. Lefkowitz | Director | 158,103 |
| Alan W. Dunton | Director | 70,703 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Todisco | $6.10M | $8.87M | $3.75M | $276 | – |
| FY2024 Todisco | $2.36M | $5.39M | $1.11M | $192 | – |
| FY2023 Todisco | $2.46M | $1.87M | $1.18M | $89 | – |
| FY2022 David | $1.14M | $798.47K | $933.72K | $93 | – |
| FY2022 Todisco | $2.69M | $3.21M | $933.72K | $93 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of February 28, 2026 we employed approximately 191 full-time employees,”
Corporate history
Events identified from SEC filings